Prevalence and Clinical Associations of CXCR4-Using HIV-1 Among Treatment-Naive Subtype C-Infected Women in Botswana
暂无分享,去创建一个
D. Kuritzkes | S. Lockman | M. Essex | L. Smeaton | R. Mitchell | V. Novitsky | S. Moyo | N. Lin | J. Makhema | Francoise F. Giguel
[1] R. Beroukhim,et al. The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates. , 2010, Journal of virological methods.
[2] M. Hughes,et al. Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. , 2009, The Journal of infectious diseases.
[3] Paolo Piazza,et al. Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study. , 2008, The Journal of infectious diseases.
[4] Bernard Hirschel,et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. , 2008, The New England journal of medicine.
[5] A. Capovilla,et al. Genotypic characterization and comparison of full-length envelope glycoproteins from South African HIV type 1 subtype C primary isolates that utilize CCR5 and/or CXCR4. , 2008, AIDS research and human retroviruses.
[6] A. Capovilla,et al. Emergence of X4 usage among HIV-1 subtype C: evidence for an evolving epidemic in South Africa , 2008, AIDS.
[7] S. Lagakos,et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. , 2007, The New England journal of medicine.
[8] J. Mullins,et al. Prevalence and genetic diversity of HIV type 1 subtypes A and D in women attending antenatal clinics in Uganda. , 2007, AIDS research and human retroviruses.
[9] P. Kaleebu,et al. Relation Between Chemokine Receptor Use, Disease Stage, and HIV-1 Subtypes A and D: Results From a Rural Ugandan Cohort , 2007, Journal of acquired immune deficiency syndromes.
[10] Eoin Coakley,et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] L. Ping,et al. Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. , 2006, Virology.
[12] David W. Williamson,et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. , 2006, The Journal of infectious diseases.
[13] Peter B Gilbert,et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. , 2006, JAMA.
[14] N. Graham,et al. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. , 2006, The Journal of infectious diseases.
[15] S. Lagakos,et al. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana , 2006, AIDS.
[16] L. Morris,et al. Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. , 2006, AIDS research and human retroviruses.
[17] T. Ndung’u,et al. HIV-1 subtype C in vitro growth and coreceptor utilization. , 2006, Virology.
[18] P. Harrigan,et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. , 2005, The Journal of infectious diseases.
[19] Christophe Pasquier,et al. R5 to X4 Switch of the Predominant HIV-1 Population in Cellular Reservoirs During Effective Highly Active Antiretroviral Therapy , 2005, Journal of acquired immune deficiency syndromes.
[20] B. Gazzard,et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. , 2005, The Journal of infectious diseases.
[21] Rami Kantor,et al. High Frequency of Syncytium-Inducing and CXCR4-Tropic Viruses among Human Immunodeficiency Virus Type 1 Subtype C-Infected Patients Receiving Antiretroviral Treatment , 2003, Journal of Virology.
[22] Lynn Morris,et al. The CCR5 and CXCR4 Coreceptors Are Both Used by Human Immunodeficiency Virus Type 1 Primary Isolates from Subtype C , 2003, Journal of Virology.
[23] S. Engelbrecht,et al. Change in co-receptor usage of current South African HIV-1 subtype C primary isolates. , 2002, AIDS.
[24] W. Dowling,et al. Full-length genome analysis of HIV-1 subtype C utilizing CXCR4 and intersubtype recombinants isolated in South Africa. , 2002, AIDS research and human retroviruses.
[25] R. Paranjape,et al. Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India. , 2000, Virology.
[26] P. Vernazza,et al. Characterization of V3 Sequence Heterogeneity in Subtype C Human Immunodeficiency Virus Type 1 Isolates from Malawi: Underrepresentation of X4 Variants , 1999, Journal of Virology.
[27] T. F. Rinke de Wit,et al. HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. , 1999, AIDS.
[28] J. Albert,et al. Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. , 1999, AIDS research and human retroviruses.
[29] D. Katzenstein,et al. Primary subtype C HIV-1 infection in Harare, Zimbabwe. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[30] H. Furrer,et al. Association of syncytium‐inducing phenotype of HIV‐1 with CD4 cell count, viral load and sociodemographic characteristics , 1998, AIDS (London).
[31] R. Connor,et al. Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.
[32] D. Richman,et al. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. , 1994, The Journal of infectious diseases.
[33] D. Richman,et al. A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus. , 1993, The Journal of infectious diseases.
[34] I. Keet,et al. Prognostic Value of HIV-1 Syncytium-Inducing Phenotype for Rate of CD4+ Cell Depletion and Progression to AIDS , 1993, Annals of Internal Medicine.
[35] H. Schuitemaker,et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.
[36] Huisman,et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex , 1988, Journal of virology.